Strong revenue growth and narrowing losses suggest commercial inflection for ZEO's regenerative biologics pipeline. Monitor next 10-Q for continued margin expansion and cash flow trajectory, as the company remains clinical-stage with minimal absolute revenue scale.
Price Chart
Executive Summary
Zeo ScientifiX reported strong revenue growth of 124.6% for the quarter ended April 30, 2026, reaching $2.58M, up from $1.15M a year earlier. Net loss for the six months was reduced to approximately $1.0M from $2.6M YoY, while gross margins held steady around 80%. The filing highlights accelerating commercial momentum for its regenerative biologics portfolio, though no guidance was provided and consensus estimates were absent.
Key Financial Metrics
Key Facts
- Quarterly revenue of $2,581,000 for the three months ended April 30, 2026, up 124.6% YoY from $1,149,000
- Six-month revenue of $4,027,000 for period ended April 30, 2026, up 79.9% YoY from $2,239,000
- Gross margins of approximately 80.0% maintained for both six-month periods ended April 30, 2026 and 2025
- Net loss reduced to approximately $1.0 million for six months ended April 30, 2026, compared to $2.6 million in the prior year period
- Revenue growth driven by increased allogenic biologic product sales, stem-cell-focused product demand in Florida, and expanded physician adoption
Financial Impact
Revenue increased $1.43M (124.6%) QoQ and net loss improved by ~$1.6M over the six-month period
Risk Factors
- Clinical-stage biopharmaceutical with no approved products and reliance on biologic supply business
- Revenue base remains small (~$2.58M quarterly) with limited visibility into sustainable growth rates
- No forward guidance provided; management commentary is qualitative only
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-007394 |
| Document: zeoscientifix_ex99-1.htm | 0001829126-26-007394 |
| Document: 0001829126-26-007394-index-headers.html | 0001829126-26-007394 |
| Document: 0001829126-26-007394-index.html | 0001829126-26-007394 |
| Document: 0001829126-26-007394.txt | 0001829126-26-007394 |
| 8-K Data (Synthetic) | 0001829126-26-007394 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $1.50 | awaiting T+20 | — | $1.39 (−7.33%) |
Sep 15, 2026 6w ago | 8-K | $1.36 $1.15 | ▼ −15.44% | ▼ −18.42% | $1.39 (+2.21%) |
Sep 1, 2026 8w ago | 8-K | $1.20 $1.39 | ▲ +15.83% | ▲ +14.65% | $1.39 (+15.83%) |
Aug 4, 2026 12w ago | 8-K | $1.40 $1.20 | ▼ −14.16% | ▼ −12.93% | $1.39 (−0.57%) |
Jul 21, 2026 14w ago | 8-K | $1.69 $1.55 | ▼ −8.28% | ▼ −10.85% | $1.39 (−17.75%) |
Jul 8, 2026 15w ago | 8-K | $1.80 $1.40 | ▼ −22.33% | ▼ −25.61% | $1.39 (−22.78%) |
Jul 1, 2026 16w ago | 8-K | $1.77 $1.65 | ▼ −6.78% | ▼ −4.59% | $1.39 (−21.47%) |
Jun 16, 2026 19w ago | 8-K | $1.72 $1.94 | ▲ +12.79% | ▲ +11.93% | $1.39 (−19.19%) |
Jun 9, 2026 20w ago | 8-K | $1.67 $1.80 | ▲ +7.78% | ▲ +6.39% | $1.39 (−16.77%) |
May 27, 2026 21w ago | 8-K | $1.85 $1.70 | ▼ −8.11% | ▼ −6.21% | $1.39 (−24.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers